﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Pharmaceutical Sciences</JournalTitle>
      <Issn>1735-403X</Issn>
      <Volume>30</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month>04</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Application of a Deep Eutectic Solvent for the Synthesis of Novel Imidazole-Containing Quinazoline Derivatives as Potent Cytotoxic Agents</ArticleTitle>
    <FirstPage>215</FirstPage>
    <LastPage>228</LastPage>
    <ELocationID EIdType="doi">10.34172/PS.2023.29</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Fatemeh</FirstName>
        <LastName>Azmian Moghadam</LastName>
        <Identifier Source="ORCID">https://orcid.org/0009-0005-4010-9478</Identifier>
      </Author>
      <Author>
        <FirstName>Sara</FirstName>
        <LastName>Dabirian</LastName>
      </Author>
      <Author>
        <FirstName>Amin</FirstName>
        <LastName>Ebrahimi Tavani</LastName>
      </Author>
      <Author>
        <FirstName>Parisa</FirstName>
        <LastName>Alipour</LastName>
      </Author>
      <Author>
        <FirstName>Mohammad</FirstName>
        <LastName>Mojabi</LastName>
      </Author>
      <Author>
        <FirstName>Mehdi</FirstName>
        <LastName>Evazalipour</LastName>
      </Author>
      <Author>
        <FirstName>Fatemeh</FirstName>
        <LastName>Yousefbeyk</LastName>
      </Author>
      <Author>
        <FirstName>Saeed</FirstName>
        <LastName>Ghasemi</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0003-2007-2063</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/PS.2023.29</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>09</Month>
        <Day>09</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2023</Year>
        <Month>12</Month>
        <Day>11</Day>
      </PubDate>
    </History>
    <Abstract>Background: Drugs containing the 4-anilinoquinazolines scaffold play a critical role in cancer treatment by inhibiting protein kinases, especially tyrosine kinases. In this study, a novel series of 4-anilinoquinazoline derivatives were synthesized and evaluated as cytotoxic agents. Methods: All final compounds were synthesized using two methods, including a conventional approach using potassium iodide and dimethylformamide as well as a green method using a deep eutectic solvent (DES) comprising choline chloride: urea. The cytotoxicity was tested on the A431, HUVEC, and HU02 cell lines. To evaluate the binding pattern of the compounds with EGFR and VEGFR-2, a molecular docking investigation was performed. Finally, the wound healing assay was carried out to assess the potency of compounds in inhibiting cell migration.  Results: The final reaction time was approximately 15-20 min with yields of 60-72% using DES, while the conventional method took 3 to 4 h to complete, with yields between 30% and 42%. Compounds 8k and 8l showed better cytotoxicity against both cell lines compared to vandetanib (IC50=0.11 µM and 0.26 µM on A431 and IC50=5.01 µM and 5.24 µM on HUVEC, respectively). Molecular docking studies revealed that compound 8k, which contained 3-methylaniline at the 4-position of the quinazoline core, showed efficient binding affinity to both EGFR and VEGFR-2. An essential hydrogen bond was formed between quinazoline N1 of 8k and the Met796 residue of EGFR with a docking score of -8.76 kcal/mol. The imidazole N3 of 8k interacted with the Cyc919 residue of VEGFR-2, forming a hydrogen bond with a docking score of -9.03 kcal/mol. Moreover, compound 8k exhibited the best inhibitory activity on cell migration and wound healing.  Conclusion: DES significantly improved the time and yield of the final reactions. Compound 8k, which showed the best cytotoxicity and inhibitory activity on cell migration, could be a suitable candidate for further structural optimization. </Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">4-Anilinoquinazoline</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cytotoxic activity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Deep eutectic solvent</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Molecular docking</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Synthesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Wound healing assay</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>